Neuralstem Sees Breakthrough In Spinal Cord Injury

PropThink profile picture

By Jason Napodano, CFA

Earlier in the week, Neuralstem, Inc (CUR) announced the publication of preclinical data in the journal of Stem Cell Research & Therapy demonstrating that rats transplanted with its spinal cord-derived human neural stem cells, NSI-566, three days after a spinal cord injury at L3 (lumbar 3), showed improvement along several measures of motor function and a reduction of spasticity. The paper, "Amelioration of Motor/Sensory Dysfunction and Spasticity in a Rat Model of Acute Lumbar Spinal Cord Injury by Human Neural Stem Cell Transplantation," was led by principal investigator, Martin Marsala, MD, of the University of California, San Diego School of Medicine.

Results show that intraspinal grafting of NSI-566 led to a progressive and significant improvement in lower extremity paw placement (Figure A), amelioration of spasticity (Figure B), and normalization in mechanical and thermal pain/escape thresholds (Figure C) at eight weeks post-grafting.

Source: van Gorp et al, 2013

Results also showed statistically significant improvement in MRI-defined cavity and scar volume (Figure D). This suggests a cavity-filling effect by grafted cells, partially or completely, assessed by MRI.

We remind investors that back in September 2012, preclinical data was published in Cell. The study, "Long-Distance Growth and Connectivity of Neural Stem Cells After Severe Spinal Cord Injury: Cell-Intrinsic Mechanisms Overcome Spinal Inhibition," demonstrated that NSI-566 can induce regeneration of injured spinal cord axons into the graft and serve as a bridge to reconnect to gray matter motor neurons for many spinal cord injuries.

In the study, rats with surgically transected spinal cords, which rendered them permanently and completely paraplegic, were transplanted with Neuralstem's NSI-566. Similar to the data above, results showed that the animals recovered significant locomotor function, regaining movement in all lower extremity joints. Transplanted neural stem cells turned into neurons which grew a "remarkable" number of axons that extended for "very long distances" over

This article was written by

PropThink profile picture
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector. Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. Visit to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.

Recommended For You

Comments (9)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.